See more : IOL Chemicals and Pharmaceuticals Limited (IOLCP.NS) Income Statement Analysis – Financial Results
Complete financial analysis of Insmed Incorporated (INSM) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Insmed Incorporated, a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Mastersystem Infotama Tbk. (MSTI.JK) Income Statement Analysis – Financial Results
- Mera Pharmaceuticals, Inc. (MRPI) Income Statement Analysis – Financial Results
- Société Foncière Lyonnaise (0IXY.L) Income Statement Analysis – Financial Results
- AB Dynamics plc (ABDP.L) Income Statement Analysis – Financial Results
- DLH Holdings Corp. (DLHC) Income Statement Analysis – Financial Results
Insmed Incorporated (INSM)
About Insmed Incorporated
Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1 for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases; and Treprostinil Palmitil Inhalation Powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil for the treatment of pulmonary arterial hypertension and other rare pulmonary disorders. Insmed Incorporated was founded in 1988 and is headquartered in Bridgewater, New Jersey.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 305.21M | 245.36M | 188.46M | 164.41M | 136.47M | 9.84M | 0.00 | 0.00 | 0.00 | 11.50M | 11.50M | 0.00 | 4.42M | 6.92M | 10.37M | 11.70M | 7.53M | 991.00K | 131.00K | 137.00K | 150.00K | 1.96M | 296.00K | 60.00K | 663.16K |
| Cost of Revenue | 65.57M | 55.13M | 44.15M | 39.87M | 24.21M | 2.42M | 2.90M | 2.44M | 1.98M | 33.53M | 29.64M | 21.37M | 0.00 | 0.00 | 0.00 | 0.00 | 576.00K | 1.49M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -86.57K |
| Gross Profit | 239.64M | 190.23M | 144.31M | 124.54M | 112.26M | 7.41M | -2.90M | -2.44M | -1.98M | -22.03M | -18.14M | -21.37M | 4.42M | 6.92M | 10.37M | 11.70M | 6.95M | -499.00K | 131.00K | 137.00K | 150.00K | 1.96M | 296.00K | 60.00K | 749.74K |
| Gross Profit Ratio | 78.52% | 77.53% | 76.57% | 75.75% | 82.26% | 75.36% | 0.00% | 0.00% | 0.00% | -191.61% | -157.77% | 0.00% | 100.00% | 100.00% | 100.00% | 100.00% | 92.35% | -50.35% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 113.05% |
| Research & Development | 571.01M | 397.52M | 272.74M | 181.16M | 131.71M | 145.28M | 109.75M | 122.72M | 74.28M | 56.29M | 44.28M | 29.78M | 27.92M | 4.76M | 9.21M | 21.05M | 18.94M | 21.09M | 21.84M | 23.32M | 7.14M | 18.08M | 35.51M | 21.61M | 6.35M |
| General & Administrative | 344.50M | 244.98M | 234.27M | 203.61M | 210.80M | 168.22M | 79.17M | 50.68M | 43.22M | 31.07M | 22.24M | 12.66M | 12.23M | 10.26M | 0.00 | 0.00 | 0.00 | 0.00 | 5.73M | 2.98M | 3.48M | 2.98M | 4.98M | 9.55M | 0.00 |
| Selling & Marketing | 0.00 | 20.80M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.26M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 344.50M | 265.78M | 234.27M | 203.61M | 210.80M | 168.22M | 79.17M | 50.68M | 43.22M | 31.07M | 22.24M | 12.66M | 12.23M | 10.26M | 9.84M | 5.06M | 8.46M | 25.68M | 5.73M | 4.24M | 3.48M | 2.98M | 4.98M | 9.55M | 2.44M |
| Other Expenses | 33.75M | 5.05M | 5.05M | 5.00M | 4.99M | 602.00K | 300.00K | 119.00K | -33.00K | 141.00K | -33.00K | 0.00 | 12.23M | 10.26M | 9.84M | 5.06M | 8.46M | 32.79M | 5.73M | 4.24M | 3.60M | 18.37M | 95.00K | 0.00 | 2.53M |
| Operating Expenses | 949.26M | 668.36M | 512.07M | 389.77M | 347.50M | 314.75M | 188.92M | 173.40M | 117.49M | 87.37M | 66.52M | 42.44M | 40.15M | 15.01M | 19.05M | 26.11M | 27.39M | 53.87M | 27.57M | 27.56M | 10.74M | 36.45M | 40.48M | 31.16M | 8.88M |
| Cost & Expenses | 1.01B | 723.48M | 556.22M | 429.65M | 371.71M | 317.17M | 188.92M | 173.40M | 117.49M | 87.37M | 66.52M | 42.44M | 40.15M | 15.01M | 19.05M | 26.11M | 27.97M | 55.36M | 27.57M | 27.56M | 10.74M | 36.45M | 40.48M | 31.16M | 8.79M |
| Interest Income | 0.00 | 11.08M | 174.00K | 1.70M | 9.92M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.85M | 0.00 | 500.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 607.00K | 0.00 | 0.00 | 0.00 |
| Interest Expense | 81.69M | 26.45M | 40.47M | 29.56M | 27.71M | 25.47M | 5.93M | 3.50M | 2.89M | 2.42M | 2.41M | 763.00K | 10.00K | 109.00K | 781.00K | 1.26M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 10.58M | 24.27M | 27.85M | 20.08M | 10.18M | 4.83M | 2.90M | 2.44M | 1.98M | 1.07M | 680.00K | 561.00K | 343.00K | 54.00K | 707.00K | 1.04M | 406.00K | 3.37M | 12.90M | 34.00K | 96.00K | 346.00K | 1.54M | 789.00K | 86.57K |
| EBITDA | -660.18M | -429.44M | -375.09M | -250.37M | -215.67M | -293.78M | -184.10M | -170.24M | -115.28M | -86.09M | -54.20M | -40.05M | -59.31M | -6.19M | 120.32M | -13.37M | -18.87M | -49.07M | -13.79M | -27.17M | -10.49M | -34.15M | -38.64M | -30.31M | -8.04M |
| EBITDA Ratio | -216.30% | -186.75% | -198.12% | -158.03% | -169.11% | -3,106.12% | 0.00% | 0.00% | 0.00% | -758.47% | -472.77% | 0.00% | -801.13% | -116.14% | -76.81% | -109.99% | -266.08% | -4,429.97% | -11,096.95% | -19,993.43% | -6,914.00% | -830.03% | -13,055.41% | 33,536.67% | -1,212.93% |
| Operating Income | -709.63M | -478.12M | -367.76M | -265.23M | -235.25M | -307.34M | -188.92M | -173.40M | -117.49M | -87.37M | -55.02M | -42.44M | -61.72M | -8.09M | -8.67M | -14.41M | -20.44M | -54.37M | -27.43M | -27.43M | -10.59M | -37.02M | -40.19M | -81.54M | -8.13M |
| Operating Income Ratio | -232.51% | -194.87% | -195.14% | -161.32% | -172.38% | -3,124.94% | 0.00% | 0.00% | 0.00% | -759.70% | -478.39% | 0.00% | -1,397.31% | -116.92% | -83.62% | -123.18% | -271.47% | -5,486.68% | -20,941.98% | -20,018.25% | -7,057.33% | -1,893.81% | -13,576.35% | -135,891.67% | -1,225.98% |
| Total Other Income/Expenses | -37.39M | -2.03M | -61.32M | -27.46M | -18.32M | -16.74M | -4.00M | -2.78M | -2.66M | -2.22M | -2.28M | -1.14M | -23.94M | 1.74M | 127.50M | -1.26M | 477.00K | -1.77M | -13.50M | 222.00K | 288.00K | 607.00K | 3.02M | 1.87M | 0.00 |
| Income Before Tax | -747.01M | -480.15M | -436.41M | -292.69M | -253.56M | -324.08M | -192.92M | -176.18M | -120.15M | -89.58M | -57.29M | -41.37M | -59.66M | -6.36M | 118.83M | -15.67M | -19.96M | -56.14M | -40.93M | -36.42M | -10.30M | -36.42M | -37.17M | -79.66M | 0.00 |
| Income Before Tax Ratio | -244.76% | -195.69% | -231.57% | -178.02% | -185.80% | -3,295.13% | 0.00% | 0.00% | 0.00% | -778.97% | -498.21% | 0.00% | -1,350.78% | -91.84% | 1,145.54% | -133.92% | -265.13% | -5,664.88% | -31,243.51% | -26,581.75% | -6,865.33% | -1,862.76% | -12,557.09% | -132,770.00% | 0.00% |
| Income Tax Expense | 2.56M | 1.38M | -1.76M | 1.40M | 777.00K | 201.00K | -272.00K | 98.00K | -1.97M | -10.42M | -1.22M | 763.00K | 9.18M | 78.00K | 477.00K | 1.26M | 0.00 | 1.77M | 0.00 | -9.21M | -288.00K | 1.93M | -74.34M | 200.00K | -337.57K |
| Net Income | -749.57M | -481.53M | -434.65M | -294.09M | -254.34M | -324.28M | -192.65M | -176.27M | -118.18M | -79.16M | -56.07M | -41.37M | -59.66M | -6.43M | 118.35M | -15.67M | -19.96M | -56.14M | -40.93M | -27.20M | -10.30M | -36.42M | -37.17M | -79.86M | -7.79M |
| Net Income Ratio | -245.59% | -196.26% | -230.63% | -178.87% | -186.37% | -3,297.17% | 0.00% | 0.00% | 0.00% | -688.34% | -487.59% | 0.00% | -1,350.78% | -92.96% | 1,140.94% | -133.92% | -265.13% | -5,664.88% | -31,243.51% | -19,856.20% | -6,865.33% | -1,862.76% | -12,557.09% | -133,103.33% | -1,175.08% |
| EPS | -5.34 | -3.91 | -3.88 | -3.01 | -3.01 | -4.22 | -2.89 | -2.85 | -2.02 | -1.84 | -1.60 | -1.56 | -2.56 | -0.49 | 9.30 | -1.28 | -1.74 | -5.89 | -8.40 | -6.95 | -2.89 | -11.01 | -11.31 | -43.60 | -24.70 |
| EPS Diluted | -5.34 | -3.91 | -3.88 | -3.01 | -3.01 | -4.22 | -2.89 | -2.85 | -2.02 | -1.84 | -1.60 | -1.56 | -2.56 | -0.49 | 9.30 | -1.28 | -1.74 | -5.89 | -8.40 | -6.95 | -2.89 | -11.01 | -11.31 | -43.60 | -24.70 |
| Weighted Avg Shares Out | 140.43M | 123.04M | 112.11M | 97.61M | 84.56M | 76.84M | 66.58M | 61.85M | 58.51M | 43.02M | 34.98M | 26.52M | 23.35M | 13.25M | 12.71M | 12.21M | 11.47M | 9.53M | 4.87M | 3.92M | 3.56M | 3.31M | 3.29M | 1.83M | 315.50K |
| Weighted Avg Shares Out (Dil) | 140.43M | 123.04M | 112.11M | 97.61M | 84.56M | 76.89M | 66.58M | 61.89M | 58.63M | 43.10M | 34.98M | 26.55M | 23.35M | 13.25M | 12.73M | 12.21M | 11.47M | 9.53M | 4.87M | 3.92M | 3.56M | 3.31M | 3.29M | 1.83M | 315.50K |
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
BRIDGEWATER, N.J. , Dec. 6, 2024 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced the granting of inducement awards...
Insmed To Present at December 2024 Investor Conferences
BRIDGEWATER, N.J. , Dec. 2, 2024 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced that management will present at...
Insmed: PAH Treatment Advancement With 2nd Half 2025 Top-Line Data
Insmed Incorporated's ARIKAYCE, approved for MAC lung disease, achieved strong revenue growth in Q3 of 2024 and potential for expanded FDA approval, boosting its market opportunity. Brensocatib's NDA filing for bronchiectasis is expected in Q4 2024 and could lead to...
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
BRIDGEWATER, N.J. , Nov. 7, 2024 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced the granting of inducement awards...
Insmed To Present at November 2024 Investor Conferences
BRIDGEWATER, N.J. , Nov. 6, 2024 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced that management will present at...
Insmed (INSM) Reliance on International Sales: What Investors Need to Know
Review Insmed's (INSM) international revenue performance and how it affects the predictions of financial analysts on Wall Street and the future prospects for the stock.
Insmed's Q3 Loss Wider Than Expected, Sales In Line With Estimates
INSM posts wider-than-expected Q3 loss. The company plans to meet the FDA before 2024-end to discuss the possibility of an accelerated approval to expand Arikayce's label.
Insmed Incorporated (INSM) Q3 2024 Earnings Call Transcript
Insmed Incorporated (NASDAQ:INSM ) Q3 2024 Earnings Conference Call October 31, 2024 8:00 AM ET Company Participants Bryan Dunn – Head of Investor Relations Will Lewis – Chair and Chief Executive Officer Sara Bonstein – Chief Financial Officer Martina Flammer...
Insmed (INSM) Reports Q3 Earnings: What Key Metrics Have to Say
While the top- and bottom-line numbers for Insmed (INSM) give a sense of how the business performed in the quarter ended September 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates...
Insmed (INSM) Reports Q3 Loss, Tops Revenue Estimates
Insmed (INSM) came out with a quarterly loss of $1.27 per share versus the Zacks Consensus Estimate of a loss of $1.19. This compares to loss of $1.10 per share a year ago.
Source: https://incomestatements.info
Category: Stock Reports